Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

PURPOSE: PROSTVAC, a viral vector–based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further investigated those findings. PATIENTS AND METHODS: Patients were randomly as...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Gulley, James L., Borre, Michael, Vogelzang, Nicholas J., Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C., Pook, David W., Rathenborg, Per, Flaig, Thomas W., Carles, Joan, Saad, Fred, Shore, Neal D., Chen, Liddy, Heery, Christopher R., Gerritsen, Winald R., Priou, Frank, Langkilde, Niels C., Novikov, Andrey, Kantoff, Philip W.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2019
Sujets:
RAPID COMMUNICATION
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494360/
https://ncbi.nlm.nih.gov/pubmed/30817251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02031
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires